Lowenstein Sandler has advised Sonnet BioTherapeutics Holdings. Greenberg Traurig has advised Hyperliquid Strategies Inc. Sonnet BioTherapeutics Holdings, an oncology-focused biotechnology company, has completed its business combination...
Sonnet BioTherapeutics Completes Business Combination with Hyperliquid Strategies
Sonnet BioTherapeutics and Rorschach I LLC Announce $888 Million HYPE Cryptocurrency Treasury Reserve Strategy
Lowenstein Sandler LLP has advised Sonnet BioTherapeutics, Inc. Greenberg Traurig, LLP has represented Rorschach I LLC. Sonnet BioTherapeutics, Inc. has entered into a definitive agreement to...
ONO Pharmaceutical’s $2.4 Billion Acquisition of Deciphera Pharmaceuticals
Greenberg Traurig represented ONO Pharmaceutical Co. in the transaction. Japan-based global specialty pharmaceutical company ONO Pharmaceutical Co. announced its acquisition of Waltham, Massachusetts-based Deciphera Pharmaceuticals for...
Kakaopay Corporation’s $17 Million Acquisition of Majority Stake in Siebert Financial Corp
Greenberg Traurig, LLP acted as legal counsel to Kakaopay Corporation on the deal. Kakaopay Corporation (“Kakao Pay”), a fintech subsidiary of Korean-based conglomerate Kakao Corp., announced...
Korea Investment Corporation’s Investment in Golub Capital
Greenberg Traurig advised Korea Investment Corporation on the deal. Korea Investment Corporation (KIC), the sovereign wealth fund of the Republic of Korea, announced its strategic minority investment...
Getaround’s $1.2 Billion Merger with InterPrivate II Acquisition Corp.
Orrick advised Getaround on the deal, while Greenberg Traurig represented InterPrivate II Acquisition Corp. Latham & Watkins represented UBS Securities LLC, lead capital markets advisor to...